Adaptive dose finding single phase 2b clinical trial of psilocybin assisted psychotherapy ("PAP") in people diagnosed with treatment resistant depression
Latest Information Update: 20 Oct 2021
At a glance
- Drugs Psilocybin (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions; Therapeutic Use
- 13 Oct 2021 According to a MYND Life Sciences media release, the company's proprietary biomarker test technology will be a pivotal component of this trial seeking partial funds from a $15 million fund allocated by the Australian government.
- 13 Oct 2021 According to a MYND Life Sciences media release, this project will be led by Professor Paul Fitzgerald, of Monash University with 7 scientific collaborators from Monash University, Deakin University and the University of Sydney.
- 13 Jul 2021 New trial record